Interior web banner image


What is Inflectra?

Inflectra (infliximab-dyyb), a biosimilar to Remicade, can treat various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and other diseases by binding to and neutralizing TNF-α, a chemical messenger and a significant part of the autoimmune reaction, preventing it from interacting with its receptors on the cell. Inflectra has been shown to be essentially identical to Remicade, with no clinically meaningful differences in terms of efficacy, immunogenicity, safety, and purity.